Drugs / Fibrin Sealant (FS) Grifols
Fibrin Sealant (FS) Grifols
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01731938 | Nov 2012 → Apr 2015 | bleeding disorder, vascular-type | Grifols Biologicals, LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fibrin Sealant (FS) Grifols | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01731938 ↗ |
| Known as | Fibrin Sealant Grifols | “Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).” NCT01731938 ↗ |
| Known as | FS Grifols | “Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL...” NCT01731938 ↗ |
| Modality | Protein / enzyme biologic | “Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).” NCT01731938 ↗ |
| Route | Other | “by dripping or spraying” NCT01731938 ↗ |